Table 3 Baseline information of NSCLC patients with EGFR mutation
| Clinical factors | Patients (%) | Death | Log-rank test, p |
|---|---|---|---|
| Age | |||
| > =65 | 24 (53.3%) | 14 | 0.70 |
| < 65 | 21 (46.7%) | 9 | |
| Gender | |||
| Male | 13 (28.9%) | 7 | 0.6 |
| Female | 32 (71.1%) | 16 | |
| Race | |||
| Asian | 2 (4.4%) | 1 | 0.6 |
| Black or African American | 3 (6.7%) | 1 | |
| Not reported | 4 (8.9%) | 1 | |
| White | 36 (80.0%) | 20 | |
| Cancer Status | |||
| Tumor free | 20 (44.4%) | 6 | 0.01* |
| With tumor | 15 (33.3%) | 12 | |
| Unknow | 10 (22.2) | 5 | |
| Stage | |||
| Stage I | 22 (48.9%) | 9 | 0.6 |
| Stage II | 9 (20.0%) | 5 | |
| Stage III | 11 (24.4%) | 8 | |
| Stage IV | 2 (4.4%) | 1 | |
| Not reported | 1 (2.2%) | 0 | |